Cite

HARVARD Citation

    Lacouture, M. et al. (2013). Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert review of anticancer therapy. 13 (6), pp. 721-728. [Online]. 
  
Back to record